The importance of the B7/CD28/CTLA-4 molecules has been established in studies of antigenpresenting cell-derived B7 and its interaction with the T cell costimulatory molecule CD28. CTLA-4, a T cell surface glycoprotein that is related to CD28, can also interact with B7-1 and B7-2. However, less is known about the function of CTLA-4, which is expressed at highest levels after activation. We have generated an antibody to CTLA-4 to investigate the consequences of engagement of this molecule in a carefully defined system using highly purified T cells. We show here that the presence of low levels of B7-2 on freshly explanted T cells can partially inhibit T cell proliferation, and this inhibition is mediated by interactions with CTLA-4. Cross-linking of CTLA-4 together with the TCK and CD28 strongly inhibits proliferation and IL-2 secretion by T cells, Finally, results show that CD28 and CTLA-4 deliver opposing signals that appear to be integrated by the T cell in determining the response to activation. These data strongly suggest that the outcome of T cell antigen receptor stimulation is regulated by CD28 costimulatory signals, as well as inhibitory signals derived from CTLA-4.
R~
cent work has demonstrated that CD28, a protein expressed on resting and activated cells, is the major costimulatory molecule for proliferation of T cells (1) (2) (3) . CD28 engagement via antibodies augments the proliferation of T cells in response to immobilized anti-TCR antibodies (4) . Additionally, antibody engagement can supply costimulation to T cells encountering APCs deficient in costimulation (4, 5) and prevents the resultant anergic state that otherwise occurs in long-term clones (4) . Finally, Fab fragments of anti-CD28 can fully block proliferation by costimulation competent APCs (4) .
Several lines of evidence indicate that B7-1 (CD80) and B7-2 (CD86) (6) are the major costimulatory ligands on the APC. First, a chimeric fusion protein of CD28 binds B7-1 and B7-2 (7, 8) . Second, anti-B7 antibodies block T cell activation by a variety of APCs (9, 10) . Finally, induction of expression of B7-1 or B7-2 by transfection with cDNAs confers costimulatory activity on cells that do not otherwise provide costimulation (11) (12) (13) (14) . Interestingly, APCs and especially dendritic cells, which are thought to be involved in the early phases of T cells activation, express moderate levels of functional B7-2 without activation (6, 15) . These levels increase nearly 100-fold with overnight activation, enhancing their APC function.
B7-1 and B7-2 also bind CTLA-4, a close relative of CD28. Chimeric fusion proteins consisting of the ectodomain of CTLA-4 bind B7-1 and B7-2 (8, (16) (17) (18) and can block T cell activation by costimulation competent accessory cells (10, 12) . Notably, studies with soluble fusion protein indicate that CTLA-4 binds both B7 family members with an affinity "~20-fold higher than that of CD28. This higher affinity probably accounts for the ability of the CTLA-4 Ig fusion protein to block costimulation in vitro (10, 12) and to suppress graft rejection and antibody production in vivo (19, 20) .
While the ability of CTLA-4 fusion proteins to bind CD28 ligands and block T cell activation is clear, the function of the native molecule has been obscure. Originally identified as cDNA cloned from a subtracted CTL clone library (21) , CTLA-4 is homologous to CD28, especially in the extracellular domain, and both contain a conserved sequence motif, MYPPY, thought to be involved in B7 binding (22) . Recent work has shown that CTLA-4 mRNA is expressed within a few hours of activation (23) . Studies with mAbs to both human and mouse CTLA-4 demonstrated surface expression within 48 h of activation. However, functional studies have led to different conclusions about its role in activation. Linsley et al. in a study of human T cells found that anti-CTLA-4 antibodies enhanced proliferation of T cells activated with anti-CD3 and anti-CD28, suggesting that the function of CTLA-4 was to augment or sustain costimulation (24, 25) . Walunas et al. found that both intact and monovalent fragments of antibodies to mouse CTLA-4 enhanced T cell responses in allogeneic MLR, but that intact antibody inhibited proliferation under conditions where Fc receptor cross-linking was provided (26) . These results suggest that CTLA-4 might play a role in negative regulation of T cell activation.
We describe here an analysis of CD28 and CTLA-4 signaling on highly purified T cells, noting the presence of B7 on the T cells themselves. The results indicate that the two molecules have opposing effects on lymphokine production and proliferation, and that the outcome of T cell activation is determined by integration of signals transduced by these two molecules.
Materials and Methods
Immunization and Hybn'doma Production. 6 Round-bottomed 96-well plates were used for all assays. Where indicated, wells were coated with anti-CD3 at 0.1/xg/ml in 50-t~l vol for 2 h at 37~ then washed extensively and blocked for 30 rain at 37~ with complete RPMI 1640. T cells were added at l0 s per weli in 200/zi complete ILPMI 1640. For soluble assays, anti-CD28 was added at a 1:1,000 dilution of ascites, anti-CTLA-4 was added at 10 #g/ml, and B7 antibodies were added at 2.5 #g/ml and 10/zg/ml for anti-B7-1 and anti-B7-2, respectively. For crosslinking assays, anti-CD8 was added at 4 #g/ml, anti-CD3 was added at 5 #g/ml, anti-CTLA-4 was added at 20 #g/ml, and anti-Vy3 control antibody F536 was added to produce a constant total antibody concentration of 30 #g/ml. Polyclonal goat anti-hamster antibody (Pierce Chemical Co., Rockford, IL) was added at a final concentration of 20 #g/ml. All cultures were incubated at 37~ for 72 h, then pulsed with 1 #Ci of [3H]thymidine for an additional 16 h before harvesting. Antibody Incorporation onto Latex Microspheres. Sulfate polystyrene latex microspheres of 5 +_ 0.1 #M mean diameter were obtained from Interracial Dynamics Corporation (Portland, OR). Approximately 1 x 107 beads per ml were suspended in PBS and the indicated antibodies were incubated for 1.5 h at 370C. Anti-CD3 was added at 1 tzg/ml to deliver the antigen-specific signal, and binding solutions were normalized with control antibody 536 to maintain a constant total antibody concentration of 5 #g/rot during binding. Previous data have shown maximal binding is achieved when this concentration is added per 107 particles (36) . Beads were washed extensively with PBS and resuspended in I ml RPMI-10% FCS and allowed to block for at least 30 min at room temperature. 1@ cells were incubated in 96-well cultures with 10 s each of the indicated bead preparation.
Results

Activation Induces Expression of CTLA-4 on Both CD4 + and CD8 + T cells.
Antibody 9H10 was used to assess CTLA-4 expression on freshly isolated and activated T cells. As shown in Fig. 1 A, CTLA-4 was undetectable on freshly isolated T cells. CTLA-4 was readily detected on T cells 48 h after stimulation by addition of anti-CD3 to splenocytes, and it was returned to resting levels by 72 h. CD28 expression was not greatly altered by stimulation. CTLA-4 was expressed by both CD4 § and CD8 § T cells, with significantly higher levels on the latter.
Blockade of CTLA-4 or B7-I/2 Enhances Anti-CD28 Costimulation. To determine the functional consequences of CTLA-4 engagement, soluble anti-CTLA-4 or anti-CD28 antibodies were added singly or together to cultures of purified T cells exposed to immobilized anti-CD3. As shown in Fig. 2 , while anti-CD28 greatly enhances the minimal proliferation induced by CD3 stimulation, anti-CTLA-4 has no effect. This suggests that CTLA-4 does not function as an alternate costimulatory receptor. Despite its lack of costimulatory activity on its own, anti-CTLA-4 markedly increases T cell proliferation when given together with anti-CD28.
At least two mechanisms could account for the potentiating effects of anti-CTLA-4: enhancement of activation signals or removal of inhibitory signals. Given the observation that anti-CTLA-4 lacked costimulatory activity on its own, we favored the latter possibility-that blockade of CTLA-4 by the antibody might prevent interaction of CTLA-4 on the T cell surface with B7-1 and/or B7-2 and thus prevent delivery of an inhibitory signal. This is further suggested by the observation that anti-CTLA-4 Fab fragments have similar effects as anti-CTLA-4 mAbs in this assay system (data not shown). Since the cells used in our experiments were >99% Thyl + and contained no detectable MHC class-II + or B220 + cells, this possibility would require that the T cells themselves provide a source of ligand. As shown in Fig. 3 , flow cytometric analysis revealed that the freshly isolated T cells did indeed express significant levels of B7-2 and trace levels of B7-1.
To determine the functional consequence of B7 expression by T cells in our assay system, we determined the effects of anti-B7 antibodies on CD28-mediated costimulation. As shown in Fig. 2 , anti-B7 antibodies by themselves had no significant effect on anti-CD3-induced T cell proliferation. The addition of anti-B7 antibodies to cultures containing anti-CD28 resulted in a threefold increase in proliferation over that obtained with anti-CD28 alone. A similar increase in proliferation was obtained when chimeric CTLA-4 Ig instead of anti-B7 antibodies was added to block B7 interactions (data not shown). The magnitude of the increase was similar to that obtained when anti-CTLA-4 is added to CD28-treated cells in the absence of B7 blockade. The addition of anti-CTLA-4 to cultures in which anti-B7 antibodies are present results in no further increase in CD28 costimulation; indeed, a slight but reproducible decrease is observed.
Together, these results suggest that T cells express B7 at levels that are insufficient to provide costimulation via CD28 engagement in the assay system used. However, perhaps because of the fact that CTLA-4 has a much higher affinity than CD28 for B7 binding, these levels are sufficient to generate a signal that at least partially inhibits activation. Blockade of the CTLA-4/B7 interaction with either anti-CTLA-4 or antioB7 antibodies removes the inhibitory signal, resulting in an increase of the costimulatory effect of CD28 ligation.
Cross-linking of CTLA-4 with the TCR and CD28 Inhibits T Cell Proliferation and IL-2 Production.
The results shown 7 ? -~ ,27. t Figure 3 . Expression of B7-2 and B7-1 on purified, freshly isolated lymph node T cells. Cells that were >99% Thyl.2 + were isolated and stained with GL1 (anti-B7-2), 1610A (anti-B7-1), or irrelevant antibodies.
in Fig. 2 suggested that soluble, bivalent anti-CTLA-4 antibody was effective in blocking B7-mediated signals, but was inefficient in providing signals. We next examined the effects of using anti-hamster Ig to cross-link CD3, CD28, and CTLA-4 singly or together. As shown in Fig. 4 , no proliferation was obtained when CD3, CD28, or CTLA-4 were crosslinked individually. As expected, cross-linking of CD3 together with CD28 resulted in potent costimulation, while cross-linking of CD3 and CTLA-4 had no effect. Co-crosslinking of CTLA-4 together with CD3 and CD28 consistently resulted in a 5-to 10-fold reduction in proliferation. This inhibition was largely reversed by the addition of IL-2 to the cultures, suggesting that the effect is not caused by toxicity. Finally, cross-linking of CTLA-4 with CD3 and CD28 also resulted in a profound decrease in IL-2 production in the cultures (Fig. 4 B) . These results demonstrate that CTLA-4 can deliver signals that inhibit T cell responses to TCR ligation, and that the effects observed in the experi- Figure 4 . Cross-linked anti-CTLA-4 can diminish both proliferation and lymphokine production by purified LN T cells. 10s BALB/c LN T cells were cultured with the indicated hamster antibodies together with control hamster antibodies. Anti-hamster Ig antibody was added at 20 /~g/ml to cross-link. Where indicated, anti-CD3 was added at 5 ~tg/ml, anti-CD28 was added at 4 ~g/ml, anti-CTLA-4 was added at 20 #g/ ml, and control was added to normalize antibody concentration at 30 p.g/ml.
(a) Calls were cultured for 72 h, pulsed with 1 ~Ci [3H]thymidine, and harvested after an additional 16 h. (b) Supernatants were removed and analyzed for II.-2 production at 48 h using an ELISA detection system. ment presented in Fig. 2 most likely result from perturbation of B7/CTLA-4 interactions.
CD28 and CTLA-4 Deliver Quantitatively Opposing Signals.
The preceding data indicate that CTLA-4 cross-linking in the presence of CD28 signaling can inhibit IL-2 secretion and proliferation. We next sought to determine whether signaling above the threshold for CTLA-4 inhibition is independent of the magnitude of CD28 costimulation, or whether the threshold increases as CD28 signaling increases. To address this issue, T cells were stimulated by incubation with polystyrene beads coated with a constant amount of anti-CD3 and varying amounts of anti-CD28 and anti-CTLA-4. As shown in Fig. 5 , costimulation with increasing amounts of anti-CD28 in the absence of anti-CTLA-4 resulted in a gradual increase in proliferation, reaching at the highest dose a 1,500-fold increase over that obtained with anti-CD3 alone. The addition of increasing amounts of anti-CTLA-4 reduced that proliferation in a stepwise manner at all doses of anti-CD28. These results suggest that T cells integrate signals from CD28 with signals from CTLA-4, and the balance of these signals regulates the magnitude of the response to TCR ligation.
Discussion
The results presented here clearly demonstrate that CTLA-4 does not serve as a functional alternative to CD28 in providing costimulatory signals to T cells. This finding is in agreement with earlier studies showing that CTLA-4 did not replace CD28 function in CD28 mutant mice (37) . The finding that anti-CTLA-4 increases proliferation of T cells activated by anti-CD3 and anti-CD28 is in agreement with the results of Linsley et al. (24) . However, the fact that a similar result is obtained when blocking antibodies to B7 are included suggests that this apparent cooperativity of CTLA-4 is in fact a result of removal of preexisting inhibitory B7-CTLA-4 in- teractions by the soluble CTLA-4 antibodies rather than a synergism between the two antibody-generated signals. The ability of CTLA-4 to directly signal is supported by the fact that cross-linking of anti-CTLA-4, either with second antibody or by presentation immobilized on beads, results in inhibition of both IL-2 production and proliferation. This direct demonstration of signaling by CTLA-4 supports the report of Walunas et al. (26) that CTLA-4 is a negative regulator of T cell activation.
Our demonstration of a dynamic competition between CD28 and CTLA-4 indicates that in addition to CD3 and CD28 signal integration, there exists an integration point for CTLA-4-derived signals. At present there is little knowledge of the biochemical events that follow CD28 or CTLA-4 ligation. There have been reports that CD28 stimulation results in induction of protein tyrosine kinase activity (38) , and recent evidence suggest the Tec family kinase ITK represents one associated protein kinase (39) . In addition, it has been demonstrated that phosphoinositides accumulate in T cells stimulated by ligation of CD28 with B7-1, suggesting an involvement of phosphatidylinositol 3'-kinase (PI3K) 1 with CD28 (40) . In this regard, it is of interest that the cytoplasmic domains of both CD28 and CTLA-4 contain the sequence YM/VXM, a motif found in several growth factor receptors that associate with PI3K (41, 42) . Several recent reports have documented a stimulation-induced association between CD28 and PI3K, and it has been reported that mutation of the PI3K-binding motif destroys the costimulatory activity of CD28 (43) (44) (45) (46) (47) . These findings strongly suggest that binding of PI3K plays an important role in CD28 signaling. With respect to CTLA-4, however, there have been contradictory findings. Whereas a chimeric protein containing the cytoplasmic domain of CTLA-4 was unable to bind PI3K (46), another study 1 Abbreviation used in this paper: PI3K, phosphatidylinositol 3'-kinase.
reported the coprecipitation of PI3K activity with CTLA-4 (48). In any event, these findings raise the possibility that CD28 and CTLA-4 might compete for PI3K and affect its role in subsequent signal transduction.
It is also possible that CD28 and CTLA-4 signals might intersect at later stages in the pathway. It has been demonstrated that the CD28 and CD3 pathways intersect at the level of the MAP kinase JNK (49) . CTLA-4 might in someway interfere with this coupling, thus preventing costimulation. Finally, it is possible that CTLA-4 signals might interfere with those of CD28 even further downstream by interfering with IL-2 transcriptions or mRNA stabilization (46, 50) .
Our results further suggest that regulation of the outcome of T cell stimulation is a complex process with regard to events at the cell surface. It is clear that in the absence of costimulatory signals provided by the B7 family, T cells do not proliferate. It appears that even small amounts of B7, such as those present on T cells themselves, are ineffectual in supporting CD28-mediated costimulation of anti-CD3 responses. This appears to be less a consequence of the absence of CD28 signal being delivered, but rather a result of an inhibitory signal delivered through CTLA-4. This implies that either CTLA-4 is quickly expressed after activation and aborts the response, or that CTLA-4 is expressed at functionally significant levels on resting T cells. At higher levels of B7 expression, as might be encountered on activated dendritic cells and activated B cells, CTLA-4 expression on the T cells might become limiting, and the costimulation provided by CD28 becomes dominant. As expression of CTLA-4 rises after activation, the signals generated through CTLA-4 might become dominant and terminate the response. Decay of CTLA-4 expression with time would allow the T cell to return to a state where the CD28 costimulatory signal would predominate. In any event, accumulating evidence suggests that in addition to antigen receptor and CD28-mediated signals, a third signal, provided by CTLA-4, is important in determining the outcome of T cell activation.
